The global PET imaging agents market is shifting from broad metabolic imaging toward molecularly targeted radiotracers that guide cancer staging, treatment selection and monitoring. 18F-FDG remains essential, but PSMA-targeted, amyloid, tau, somatostatin-receptor and cardiac tracers are changing purchasing decisions. Nuclear pharmacies, isotope supply, regulatory clearance and local dose availability now shape competition as much as clinical sensitivity.
DataM Intelligence estimates the global PET radiotracer market at US$4.10 billion in 2025, reaching US$8.55 billion by 2035, with a 7.62% forecast CAGR. North America held 45.2% of 2025 revenue, while Asia-Pacific is the fastest-growing major region. Oncology represented approximately 62.4% of demand. The competitive opportunity therefore lies in scaling targeted tracers while preserving dependable short-half-life production and distribution.
GE HealthCare CEO Peter Arduini described 2025 progress as a strategy focused on “precision care, growth acceleration, and business optimization,” citing growth in Pharmaceutical Diagnostics. In announcing the proposed Curium–Lantheus combination in August 2026, Lantheus emphasized a platform spanning diagnostics and therapy, illustrating the strategic value of integrating radiotracers, manufacturing and commercialization. (GE HealthCare, 4 February 2026; Curium/Lantheus, 3 August 2026.)
Request Exclusive Sample: https://www.datamintelligence.com/download-sample/pet-radiotracer-market
Top 10 Companies Analysis
Lantheus Holdings
Lantheus is a leading U.S. molecular imaging supplier built around PYLARIFY (piflufolastat F 18), alongside PET neurology products. FY2025 consolidated revenue was US$1.542 billion; PYLARIFY generated US$989.1 million. Its strategic strength is an established PSMA imaging franchise and commercial reach. A proposed merger with Curium announced in August 2026 could broaden global manufacturing and distribution, subject to closing conditions.
Curium
Curium supplies PET and SPECT radiopharmaceuticals through a wide manufacturing and distribution footprint. Its position spans oncology imaging, nuclear pharmacy services and theranostics development. It announced an agreement to acquire Lantheus in August 2026, potentially expanding its U.S. PET portfolio. Comparable consolidated 2025 revenue is not publicly disclosed.
Telix Pharmaceuticals
Telix has commercialized prostate-cancer PET products and expanded into additional precision-medicine tracers. FY2025 revenue was US$803.8 million, up 56%. In September 2026, FDA approval of F-18-FET Pixclara created a differentiated glioma-imaging offering. The company is building radiopharmacy access alongside diagnostic and therapeutic pipelines.
GE HealthCare
GE HealthCare combines pharmaceutical diagnostics, PET tracers and imaging-system relationships. FY2025 company revenue was US$20.625 billion, including US$2.900 billion in its broader Pharmaceutical Diagnostics segment. Its radiopharmaceutical reach supports amyloid, cardiac and oncology imaging; company-wide revenue should not be treated as PET-agent-only sales.
Bracco / Blue Earth Diagnostics
Bracco participates in molecular imaging through Blue Earth Diagnostics, including POSLUMA (flotufolastat F 18) for prostate-cancer PET. Its challenge is to grow agent adoption and production-network coverage against established PSMA competitors. Bracco is privately held; a comparable verified 2025 PET-agent revenue figure is not disclosed.
Cardinal Health
Cardinal Health is an important radiopharmaceutical distribution and nuclear pharmacy provider in the U.S. Its strategic leverage comes from dose preparation and last-mile delivery rather than ownership of every tracer brand. The company reports broad healthcare distribution results; PET imaging agents are not separately disclosed as a comparable 2025 revenue line.
Jubilant Radiopharma
Jubilant Radiopharma operates radiopharmacy and radiopharmaceutical networks serving hospitals and imaging centers. Its competitiveness is anchored in regional dose availability, service and PET manufacturing capacity. Parent-company revenues span additional businesses, and directly comparable FY2025 PET-agent-only sales are not separately identified.
Siemens Healthineers / PETNET Solutions
PETNET Solutions provides PET radiopharmaceutical manufacturing and distribution services, particularly FDG, connecting a broad imaging ecosystem with regional isotope logistics. Its advantage is an established production network. PETNET revenue is not published separately on a verified 2025 basis.
PDRadiopharma / PeptiDream
Japan-based PDRadiopharma, part of PeptiDream, is relevant through radiopharmaceutical manufacture and next-generation precision-imaging programs. Local hospital relationships and clinical development support its positioning in Asia. Consolidated parent revenue is not directly comparable with a PET-agent revenue series.
Ionetix
Ionetix is an emerging U.S. radiopharmaceutical supplier developing PET dose networks, including Ga-68 PSMA imaging capabilities. It is strategically focused on reducing distribution bottlenecks through multi-site production. A comparable consolidated 2025 revenue figure is not publicly verified.
Competitor Analysis: Leading PET Imaging Agents Market Players
| Company | Core Position | 2025 Revenue (USD) | Strategic Focus |
| Lantheus | PSMA PET / neurology | US$1.542bn; group | PYLARIFY / targeted PET |
| Curium | PET manufacturing / distribution | Not disclosed | Global radiopharmacy scale |
| Telix | PSMA and FET tracers | US$803.8m; group | Pixclara / specialty imaging |
| GE HealthCare | Radiopharma + imaging | US$20.625bn; group | PDx segment US$2.900bn |
| Bracco / Blue Earth | Targeted PSMA PET | Not disclosed | POSLUMA |
| Cardinal Health | Nuclear pharmacy network | PET sales not disclosed | Regional dose distribution |
| Jubilant Radiopharma | PET production / pharmacies | PET sales not disclosed | Supply reliability |
| Siemens / PETNET | FDG manufacturing network | PETNET not disclosed | Cyclotron-scale logistics |
| PDRadiopharma | Japan radiopharmaceuticals | PET sales not disclosed | Local clinical partnerships |
| Ionetix | PET radiopharmacy expansion | Not disclosed | Ga-68 PSMA dose access |
Request Exclusive Sample: https://www.datamintelligence.com/download-sample/pet-radiotracer-market
Reported company revenues are consolidated unless stated otherwise. Revenue is not equivalent to the size of each company’s PET imaging agents business.
Who Are the Rising Companies Influencing the Market?
- Ionetix - Strategic focus: expand Ga-68 PSMA PET manufacturing sites and improve dose availability close to hospitals.
- PeptiDream / PDRadiopharma - Strategic focus: advance targeted imaging candidates through Japanese development and radiopharmaceutical supply channels.
- Life Molecular Imaging - Strategic focus: deepen neurological PET imaging and tracer access for Alzheimer’s care pathways.
- Specialist regional nuclear pharmacies - Strategic focus: reduce wasted doses and extend tracer coverage beyond major metropolitan hospitals.
Major Mergers, Acquisitions and Portfolio Restructuring - 2026
- 3 August 2026 - Curium announced a definitive agreement to acquire Lantheus for consideration of up to US$8.0 billion. The proposed combination connects major U.S. diagnostic radiopharmaceutical franchises with Curium’s global supply platform; closing is subject to approvals.
- 21 September 2026 - Telix announced a strategic agreement to combine with isotope producer ITM. The transaction includes US$1.65 billion upfront consideration and up to US$700 million in milestones. Its direct emphasis is therapeutic isotopes, with broader implications for integrated theranostics.
Recent Innovations and Their Potential Impact - June 2026 Onward
- 2 June 2026 - Telix and United Imaging announced a research collaboration to assess integrated tracer, scanner and clinical workflow solutions. Potential impact: more standardized PET protocols and imaging throughput.
- 14 September 2026 - The FDA approved Telix’s Pixclara (18F-FET) to distinguish recurrent or progressive glioma from treatment-related changes. Potential impact: expands commercially approved PET imaging beyond established FDG and PSMA indications.
- 30 September 2026 - Telix received FDA Fast Track designation for BiPASS, studying Ga-68 PSMA PET with MRI before prostate biopsy. Potential impact: could move molecular imaging earlier in the diagnostic pathway if pivotal outcomes support approval.
- 6 October 2026 - Telix reported the first U.S. patients dosed with commercially available Pixclara. Potential impact: converts regulatory approval into a functioning clinical supply chain and early provider adoption.
What Is Driving Competition in the Market?
Target-specific clinical utility is becoming the central differentiator. PSMA and glioma agents can answer questions that FDG alone may not resolve. Neurological tracers are likewise gaining importance as treatment pathways require more precise biomarker evidence. These changes favor suppliers able to generate clinical data, secure reimbursement and demonstrate value in actual care decisions.
Distribution remains an unusually high barrier to entry. F-18 has a roughly 110-minute half-life, while Ga-68 has a shorter distribution window. Commercial growth therefore relies on cyclotrons, quality control, licensed pharmacies, hospital scheduling and reliable dose delivery. Radiopharmaceutical companies with dense local networks can defend share even when competing tracers demonstrate similar clinical performance.